India’s Aurobindo buys Sandoz US assets from Novartis
The transaction underpins Novartis's strategy of achieving sustainable and profitable growth in the US in the long term.
Keystone
Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a $900 million (CHF870 million) cash payment.
This content was published on
2 minutes
A possible performance-related payment of $100 million could be added to the purchase price, the Swiss AWP financial news agency reported.
The divested business generated sales of $600 million in the first half of 2018. It includes approximately 300 products and development projects.
A Novartis spokesman refused to comment on whether other parts of the Sandoz portfolio in the United States were still for sale.
750 employees affected
The production facilities in Wilson, North Carolina, as well as in Hicksville and Melville, New York, will also be transferred to Aurobindo.
In this context, approximately 750 employees and the sales force of the dermatology business PharmaDerm will be transferred to the Indian company upon completion of the transaction.
Novartis said the transaction is expected to close during 2019.
Focus on complex generics
Sandoz will focus instead on complex generics, value-added medicines and biosimilars.
The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. “With this transaction, we are focusing our business,” Sandoz CEO Richard Francis was quoted as saying.
The Sandoz portfolio will remain “strong” even after the transaction, according to the company statement. It includes injectables, respiratory products and ophthalmics.
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
Switzerland to step up humanitarian aid to Lebanon and Syria
This content was published on
The Swiss government decided to allocate an additional CHF7 million to the two countries in response to the escalating violence in the Middle East.
Report exposes widespread hygiene issues in Swiss hospitals
This content was published on
A Swissmedic report found that nearly all of the 25 Swiss hospitals inspected had issues with disinfecting, sterilising and packaging of medical products.
Swiss bank Mirabaud closes brokerage unit due to poor performance
This content was published on
The move spanning the bank’s global operations means a loss of 17 jobs, including five each in Switzerland and the UK, and seven in Spain.
Guterres condemns Israel’s plan to label UNRWA a terrorist organisation
This content was published on
UN Secretary-General Antonio Guterres has spoken out against a law proposed by the Israeli parliament that would classify UNRWA as a terrorist organisation.
This content was published on
The Swiss federal technology institute ETH Zurich is the best university in continental Europe, according to the Times Higher Education ranking.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis chief hints at job cuts in Switzerland
This content was published on
The president of pharmaceutical giant Novartis has announced job cuts in an interview with Swiss newspaper NZZ am Sonntag.
This content was published on
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time…
Eye on the Multinationals: Your questions become our stories
This content was published on
Do you work for or would like to work for a multinational company? Are you concerned about the impact of multinational companies at home and abroad?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.